title: Cardioversion for atrial fibrillation in current European practice: results of the European Heart Rhythm Association survey.
abstract: This survey was conducted to provide an insight into the current clinical practice regarding the use of cardioversion for atrial fibrillation (AF) in Europe. Responses were received from 57 centres across Europe, 71.9% of which were university hospitals. For electrical cardioversion, general anaesthesia was managed by an anaesthesiologist in 73.9% of centres and by a cardiologist in 37%. In the majority of centres, electrical cardioversion was performed using a biphasic defibrillator (85.1%). Antiarrhythmic drugs were routinely prescribed prior to electrical cardioversion by 54.3% of hospitals. For pharmacological cardioversion in patients with no or minimal heart disease, the majority of centres (63.1%) chose intravenous flecainide or propafenone, whereas vernakalant was used by 35% of centres in patients with no or minimal-to-moderate structural heart disease. Most centres (71.7%) used a mandatory strategy of 3 weeks of oral anticoagulation prior to elective cardioversion in patients AF > 48 h, but 28.3% performed immediate cardioversion after a transoesophageal echocardiogram. Many centres are now performing electrical cardioversion on treatment with novel oral anticoagulants (up to 23.6% of cardioversions).
authors.affiliation: Cardiology Department, Ramón y Cajal Hospital, Carretera Colmenar Viejo, km 9, 100, 28034 Madrid, Spain. antoniomadri@gmail.com
authors.forename: Antonio
authors.initials: A
authors.lastname: Hernández-Madrid
authors.forename: Jesper Hastrup
authors.initials: JH
authors.lastname: Svendsen
authors.forename: Gregory Y H
authors.initials: GY
authors.lastname: Lip
authors.forename: Isabelle C
authors.initials: IC
authors.lastname: Van Gelder
authors.forename: Dan
authors.initials: D
authors.lastname: Dobreanu
authors.forename: Carina
authors.initials: C
authors.lastname: Blomstrom-Lundqvist
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000453:epidemiology* / Q000517:prevention & control*; D015897:Comorbidity; D004554:Electric Countershock; D005060:Europe / Q000453:epidemiology; D019538:Health Care Surveys; D006801:Humans; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D015995:Prevalence; D012307:Risk Factors; D013923:Thromboembolism / Q000453:epidemiology* / Q000517:prevention & control*
chemical_list: D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants
keywords: Anticoagulation; Atrial fibrillation; Cardioversion; EHRA survey; Rhythm control